Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00712855 · ClinicalTrials.gov registry record · Phase 1
A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
A Phase 1 study, sponsored by Human Genome Sciences Inc., a GSK Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00712855 is a Phase 1 study that has completed, run by Human Genome Sciences Inc., a GSK Company. The registered enrollment target is 23 participants.
The verdict
NCT00712855, a Phase 1 study, has completed, sponsored by Human Genome Sciences Inc., a GSK Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of escalating doses of mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma who are positive for hepatitis B surface antigen or hepatitis C antibody.
Interventions
- DRUG sorafenib
- BIOLOGICAL mapatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00712855
The ClinicalTrials.gov registry entry for NCT00712855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences Inc., a GSK Company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sorafenib is the first listed.
NCT00712855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00712855 about?
NCT00712855 is a clinical study titled "A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma". The purpose of this study is to evaluate the safety and tolerability of escalating doses of mapatumumab in combination with sorafenib in subjects with advanced Hepatocellular Carcinoma who are positive for hepatitis B surface antigen or hepatitis C antibody.
What is the current status of trial NCT00712855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00712855?
The interventions under investigation include: sorafenib (DRUG), mapatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00712855?
This trial is sponsored by Human Genome Sciences Inc., a GSK Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.